Clinical and Translational Allergy最新文献

{"title":"Association of ZNF608 Polymorphisms With House Dust Mite-Induced Allergic Rhinitis","authors":"Huiqin Li,&nbsp;Fang Gao,&nbsp;Xuyan Liu,&nbsp;Haoran Shen,&nbsp;Mulong Du,&nbsp;Lei Cheng,&nbsp;Huihui Zhang,&nbsp;Zhengdong Zhang,&nbsp;Meiping Lu,&nbsp;Rui Zheng","doi":"10.1002/clt2.70081","DOIUrl":"https://doi.org/10.1002/clt2.70081","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Genetic factors contribute essentially to the pathophysiology of house dust mite (HDM)-induced allergic rhinitis. Previous studies mainly focused on the biological pathogenesis, but the heritability remains poorly explained.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A genome-wide gene association analysis (GWGAS) integrating joint-genetic variant effects at the gene level was initially conducted on allergic rhinitis, validated by differential gene expression analysis. A weighted polygenic risk score (wPRS) was used to proxy the cumulative effect of candidate genetic variants in key genes. Gene-set analysis and eQTL analysis were performed to explore the immunologic pathway and genetic regulation of the key gene.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p><i>ZNF608</i> was identified as the key gene involving HDM-induced allergic rhinitis risk (<i>p</i> = 1.23 × 10⁻⁶), which was highly expressed in nasal epithelium cells of allergic rhinitis patients (<i>p</i> = 0.041). Furthermore, a wPRS of five significant variants, rs6862252, rs10067299, rs10042766, rs6866116, and rs79679768 in the <i>ZNF608</i>, showed the cumulative effect was associated with the increased HDM-induced allergic rhinitis risk (odds ratio [OR] = 1.40, 95% confidence interval [CI] = 1.18–1.65, <i>p</i> = 1.18 × 10⁻⁴), with varied effects under diverse conditions of nasal symptoms. Additionally, both rs6862252 G allele and rs10042766 T allele elevated the expression of <i>ZNF608</i> involving in state and perturbation of immune cells, such as B cell, T cell, and dendritic cell, contributing to HDM-induced allergic rhinitis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study highlights the key gene <i>ZNF608</i> of HDM-induced allergic rhinitis, which may lay the groundwork for risk assessment and early diagnosis of allergic rhinitis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 8","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70081","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144782786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic and Environmental Contributions to Serological Biomarkers of Extracellular Matrix Remodeling in Asthma: A Twin Study","authors":"Matej Andelic,&nbsp;Vibeke Backer,&nbsp;Kirsten Ohm Kyvik,&nbsp;Signe Holm Nielsen,&nbsp;Simon Francis Thomsen","doi":"10.1002/clt2.70089","DOIUrl":"https://doi.org/10.1002/clt2.70089","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Asthma is characterized by airway obstruction driven by chronic inflammation, leading to extracellular matrix (ECM) remodeling. This involves ECM alterations, including increased collagen deposition and elastolysis, resulting in airway wall thickening and irreversible airflow limitation. Despite ECM remodeling's known role in asthma, no reliable tools track these changes, and the genetic and environmental factors driving them remain unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study investigated ECM remodeling in asthma by assessing 12 serological neo-epitopes related to collagen synthesis, degradation, and immune cell activity. Studying monozygotic (MZ) and dizygotic (DZ) twins, we explored genetic and environmental influences on ECM changes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study included 512 individuals from 256 twin pairs (89 MZ, 167 DZ), of which 200 were healthy and 312 had asthma. An exploratory panel of 12 ECM biomarkers reflecting type III and VI collagen formation (PRO-C3, PRO-C6), turnover (PRO-C4), degradation (C3M, C4M, C4Mα3, C6M, C7M), and immune cell activity (VICM, ELP-3, ELA-HNE, CC16-HNE) was measured in serum using ELISA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Asthma was linked to increased type IV collagen degradation (C4M). Airway obstruction showed decreased PRO-C6, C4Mα3, C6M, and C7M, while C4M and ELP-3 were elevated among twins. Classical twin analyses revealed genetic influence on multiple biomarkers, primarily C4Mα3, C7M, CC16-HNE, and VICM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study highlights ECM remodeling's role in asthma and airway obstruction, identifying distinct biomarker profiles. Genetic factors significantly influence ECM changes, suggesting potential genetic predispositions for ECM alterations and offering insights into asthma pathogenesis and future diagnostic and therapeutic strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 8","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70089","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung Acetate Levels Decline in Correlation With Increased Type 2 Allergic Markers in a House Dust Mite Allergic Mouse Model","authors":"Roos E. M. Verstegen,&nbsp;Rolf W. Sparidans,&nbsp;Atanaska I. Kostadinova,&nbsp;Johan Garssen,&nbsp;Gert Folkerts,&nbsp;Rudi W. Hendriks,&nbsp;Linette E. M. Willemsen","doi":"10.1002/clt2.70082","DOIUrl":"https://doi.org/10.1002/clt2.70082","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Microbial dysbiosis is an important feature in allergic asthma. Short-chain fatty acids (SCFA) produced by the intestinal microbiome play a role in the gut-lung axis. Little is known about how the gut SCFA levels reflect SCFA levels in other tissues and how these link to the allergic asthma inflammatory status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Male BALB/c mice were intranasally exposed to house dust mite (HDM) to induce allergic airway inflammation. Acetate, propionate, and butyrate levels were determined in caecum content, serum and lungs of control and HDM-allergic mice using liquid chromatography-mass spectrometry. Faecal microbiome composition was determined by DNA sequencing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Mean acetate:propionate:butyrate ratios were 75:15:10 in caecum content, 98:1.5:0.5 in serum, and 38:61:1 in the lung. SCFA levels did not correlate across compartments and propionate was relatively high in the lungs. The faecal microbiome of allergic mice differed from control, with increased Desulfovibrionaceae abundance. The lung acetate proportion was lower in allergic mice compared to control. In allergic mice, declining lung acetate levels correlated with increased HDM-specific IgE in serum and IL-13 release by ex vivo HDM-restimulated lung cells. Ex vivo acetate supplementation did not inhibit HDM-restimulated lung cell IL-13 production, while butyrate and propionate did.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Overall, HDM-driven murine allergic airway inflammation induced changes in the faecal microbiome and reduced acetate in serum and lung tissue. Hereby, lung acetate levels correlated negatively with sensitisation and type-2 inflammation, but acetate itself did not suppress ex vivo HDM-induced cytokine release. Our findings provide new insights on the systemic effects of HDM-allergic inflammation along the gut-lung axis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 8","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70082","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges of Transitional Care for Young Allergy and Asthma Patients From Healthcare Professionals' Perspectives","authors":"Maria Ödling,&nbsp;Birgitta Lagercrantz,&nbsp;Susanne Lundin,&nbsp;Hanna Sandelowsky,&nbsp;Christer Janson,&nbsp;Inger Kull","doi":"10.1002/clt2.70088","DOIUrl":"https://doi.org/10.1002/clt2.70088","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Evidence-based guidelines for transitional care of adolescents and young adults with allergy and asthma have been published, but shortcomings in the transition process have been identified. This study's aim was to gather deeper insights into healthcare professionals' experiences regarding the challenges of transitional care for adolescents and young adults with allergy and asthma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Clinically active physicians and registered nurses in Sweden were recruited through a web survey. Qualitative data were obtained through individual interviews (<i>n</i> = 18). The transcribed interview data, serving as the basis for this study, were analysed using systematic text condensation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Four categories emerged during the analysis process: (1) ‘There is no clear structured approach that can be applied to everyone’, addressing variations in disease and individual patient needs. (2) ‘Relying only on referrals’, indicating that no other forms of communication exist. (3) ‘Tackling patients’ assumptions and verifying their knowledge’, referring to discrepancies between patients' expectations of healthcare professionals' knowledge of medical histories and the limited information actually available to healthcare professionals. (4) ‘Unprepared patients in a fragmented care chain’, implying a need to prepare patients for how healthcare services can differ.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Based on healthcare professionals' experiences, transitional care for patients with allergies and asthma is a complex process marked by numerous challenges. Interventions for improvement should include increased guideline implementation at all levels of healthcare, better communication between healthcare professionals, and continuous patient education, including teaching adolescents and young adults to take responsibility for navigating the healthcare system for care of allergy and asthma.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 8","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70088","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Protective Role of Galectin-3 in Airway Dilatation in Obstructive Airway Diseases.","authors":"Mariko Kogo, Hisako Matsumoto, Naoya Tanabe, Chie Morimoto, Natsuko Nomura, Hironobu Sunadome, Tadao Nagasaki, Susumu Sato, Atsuyasu Sato, Tsuyoshi Oguma, Isao Ito, Toyohiro Hirai","doi":"10.1002/clt2.70092","DOIUrl":"https://doi.org/10.1002/clt2.70092","url":null,"abstract":"","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 8","pages":"e70092"},"PeriodicalIF":4.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12328036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Adrenaline Administration in Anaphylaxis: Clinical Practice Considerations and Safety Insights.","authors":"Motohiro Ebisawa, Antonella Muraro, Margitta Worm, Constance H Katelaris, Guillaume Pouessel, Johannes Ring, George Du Toit, Adam T Fox","doi":"10.1002/clt2.70085","DOIUrl":"10.1002/clt2.70085","url":null,"abstract":"<p><strong>Background: </strong>Anaphylaxis is an acute, severe, and potentially fatal reaction marked by the fast onset of symptoms and organ involvement that may lead to death from vascular collapse or airway obstruction. Despite adrenaline (epinephrine) being the first-line medication for reversing anaphylactic symptoms, misconceptions about its safe and correct use persist and lead to improper administration.</p><p><strong>Methods: </strong>This review provides a comprehensive overview of clinical use of adrenaline autoinjectors (AAIs) in the management of anaphylaxis, key safety considerations, and pharmacokinetic/pharmacodynamic profile of three of the currently marketed AAIs.</p><p><strong>Results: </strong>When administered intramuscularly (IM) at the recommended dose for anaphylaxis, adrenaline is considered safe; however, adequate training in emergency care is essential to minimize dosage errors and mitigate safety risks. In specific situations, such as refractory anaphylaxis, intravenous (IV) administration is advised under specialized settings due to the potential risk of severe cardiovascular complications that can result from dosing errors.</p><p><strong>Conclusion: </strong>Although adrenaline can cause mild and transient side effects even when administered correctly at the recommended dosage, the potential side effects should not deter its use in critical situations such as anaphylaxis. This review aims to highlight the role of AAIs in improving patient outcomes during anaphylactic emergencies.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 8","pages":"e70085"},"PeriodicalIF":4.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12328063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Synthetic Data Allow for Smaller Sample Sizes in Chronic Urticaria Research?","authors":"Annika Gutsche, Pascale Salameh, Samad S Jahandideh, Mehran Roodsaz, Serkan Kutan, Ali Salehzadeh-Yazdi, Emek Kocatürk, Stamatios Gregoriou, Simon F Thomsen, Kanokvalai Kulthanan, Papapit Tuchinda, Joachim Dissemond, Alicja Kasperska-Zajac, Magdalena Zajac, Mateusz Zamłyński, Martijn van Doorn, Claudio A S Parisi, Jonny G Peter, Cascia Day, Cathryn McDougall, Michael Makris, Daria Fomina, Elena Kovalkova, Nikolai Streliaev, Gerelma Andrenova, Marina Lebedkina, Maryam Khoskhkui, Mehraneh M Aliabadi, Andrea Bauer, Lea Kiefer, Melba Muñoz, Karsten Weller, Pavel Kolkhir, Martin Metz","doi":"10.1002/clt2.70087","DOIUrl":"10.1002/clt2.70087","url":null,"abstract":"<p><strong>Background: </strong>Robust data are essential for clinical and epidemiological research, yet in chronic spontaneous urticaria (CSU), certain patient groups, such as the elderly or comorbid patients, are often underrepresented. In clinical trials, strict inclusion and exclusion criteria frequently limit recruitment, making it difficult to achieve sufficient statistical power. Similarly, real-world observational studies may lack sufficient sample sizes for robust analysis. To address these limitations, we generated synthetic patient data that reflect these groups' clinical characteristics and variability. This approach enables more comprehensive analyses, facilitates hypothesis testing in otherwise inaccessible populations, and supports the generation of evidence where traditional data sources are insufficient.</p><p><strong>Methods: </strong>A tree-based decision model was applied to generate synthetic data based on an existing set of real-world data (RWD) from the Chronic Urticaria Registry (CURE). Descriptive characteristics and association strength between relevant RWD variables and their synthetic counterparts were analyzed as indicators of replication accuracy, providing insight into how closely the synthetic data aligns with the RWD. Finally, we determined the minimum sample size required to generate high-quality synthetic data.</p><p><strong>Results: </strong>The algorithm produced extensive synthetic data records, closely mirroring patient demographics and disease clinical characteristics. Smaller subgroups of the data were equally replicated and followed the same distribution as RWD. Known associations and correlations between disease-specific factors (disease control) and risk factors (age) yielded similar results, with no significant difference (p > 0.05). The lowest threshold at which synthetic data could be generated while maintaining high accuracy in RWD was identified to be 25%, enabling a fourfold increase in the synthetic population.</p><p><strong>Conclusion: </strong>Synthetic data could replicate RWD with reasonable accuracy for patients with CSU down to 25% of the original population size. This method has the potential to extend small patient subgroups in clinical and epidemiological research.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 8","pages":"e70087"},"PeriodicalIF":4.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benralizumab Depletes IL-5Rα-Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis.","authors":"Christiane E Whetstone, Ruth P Cusack, Emma L Price, Karen J Howie, Caitlin Stevens, Dhuha Al-Sajee, Suzanne Beaudin, Jennifer Wattie, Nadia Alsaji, Abbey Schlatman, Vanessa Luk, Paul M O'Byrne, Mark D Inman, Roma Sehmi, Hermenio Lima, Gail M Gauvreau","doi":"10.1002/clt2.70090","DOIUrl":"10.1002/clt2.70090","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by tissue eosinophilia and itch. We evaluated the effect of eosinophil depletion with benralizumab on markers of inflammation in the skin of patients with AD.</p><p><strong>Methods: </strong>After a 4-week washout from oral anti-inflammatory medications 20 patients with moderate to severe AD completed a randomized, double-blind, placebo-controlled parallel-group study comparing 3 doses q4wk 30 mg subcutaneous benralizumab to placebo. Lesional and unaffected skin biopsies were collected before and after 28 and 65 days of treatment, respectively, for quantification of eosinophils and IL-5Rα-bearing cells in papillary dermis. Histological measurements of epidermal thickness, spongiosis, neutrophilic and lymphocytic infiltration, as well as clinical scores EASI, SCORAD, IGA, DLQI, and POEM were conducted throughout the study. Outcomes were compared between placebo and benralizumab treatment groups using a Mann-Whitney U-test.</p><p><strong>Results: </strong>Benralizumab, compared to placebo, reduced IL-5Rα+ cells and MBP+ EG2+ eosinophils in lesions and unaffected skin (p < 0.05). In skin lesions, benralizumab reduced MBP+ eosinophils and basophils but had no effect on eosinophil progenitor (EoP; CD34+ IL-5Rα+) or mast cell numbers. There was no change in other skin histological measurements or IGA scoring of the observational lesion, nor improvement in clinical scores.</p><p><strong>Conclusion: </strong>Benralizumab treatment significantly inhibited accumulation of MBP+ eosinophils and basophils in lesional skin of patients with moderate to severe AD. However, a lack of improvement in histological and clinical outcomes suggests that other inflammatory pathways are central to the pathobiology of severe atopic dermatitis.</p><p><strong>Trial registration: </strong>(ClincialTrials.gov number, NCT03563066).</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 8","pages":"e70090"},"PeriodicalIF":4.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypersensitivity Reactions to Gadolinium-Based Contrast Agents: Update From an Allergist's Point of View","authors":"Francesca Losa,&nbsp;Giovanni Paoletti,&nbsp;Giulia Costanzo,&nbsp;Fabio Lodi Rizzini,&nbsp;Marina Mauro,&nbsp;Donatella Preziosi,&nbsp;Federica Rivolta,&nbsp;Andrea Sangalli,&nbsp;Andrea Toniato,&nbsp;Serena Traversi,&nbsp;Alessandro Vrenna,&nbsp;Mario Di Gioacchino,&nbsp;Giorgio Walter Canonica,&nbsp;Enrico Heffler,&nbsp;Maria Teresa Costantino","doi":"10.1002/clt2.70086","DOIUrl":"https://doi.org/10.1002/clt2.70086","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The increasing use of Magnetic Resonance Imaging (MRI) has led to a rise in the administration of gadolinium-based contrast agents (GBCAs), accompanied by a growing number of reported adverse events (AEs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This review aims to provide an updated overview of hypersensitivity reactions (HSRs) to GBCAs, focusing on diagnostic and management strategies from an allergological perspective.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We reviewed recent literature concerning the classification, clinical presentation, and pathophysiological mechanisms of HSRs to GBCAs. Particular attention was given to current recommendations for diagnosis, risk stratification, and prevention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>Adverse events to GBCAs are categorized into Type A reactions, which are dose-dependent and predictable, and Type B reactions, which are dose-independent hypersensitivity reactions. The latter may be allergic or non-allergic, presenting diagnostic and therapeutic challenges.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>HSRs to GBCAs, though relatively rare, require careful evaluation and tailored management. An allergological work-up, including skin testing and graded challenges when appropriate, plays a critical role in the safe re-exposure of patients with prior reactions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 8","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70086","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144716792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal Dietary Inflammatory Status and Serum Neopterin During Pregnancy: Influence on Infantile Atopic Eczema in the Offspring","authors":"Sarah El-Heis,&nbsp;Sarah R. Crozier,&nbsp;Evelyn X. Loo,&nbsp;Elizabeth H. Tham,&nbsp;Nicholas C. Harvey,&nbsp;Hazel M. Inskip,&nbsp;Southampton Women's Survey Study Group,&nbsp;Keith M. Godfrey","doi":"10.1002/clt2.70080","DOIUrl":"https://doi.org/10.1002/clt2.70080","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>A protective influence of maternal inflammatory status on infantile atopic eczema risk has been proposed, but few studies have investigated these potential links. We examined the associations between energy-adjusted dietary inflammatory index (E-DII) scores indicative of an inflammatory dietary pattern, maternal serum neopterin levels, a biomarker elevated in Th1 immune activation, and infantile risk of atopic eczema.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Within the UK Southampton Women's Survey, mothers' diets were recorded using questionnaires at preconception, early and late pregnancy and E-DII scores derived. 3006 deliveries of live born infants with no major congenital growth abnormalities who were assessed for atopic eczema at 6 or 12 months (ascertained using the UK Working Party Diagnostic Criteria [<i>n</i> = 2955 and 2871, respectively]). A sub-sample of 497 mothers had serum neopterin measured in late pregnancy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Unadjusted analyses showed that higher E-DII in preconception and late pregnancy was associated with a lower risk of eczema at ages 6 and 12 months. After adjusting for maternal BMI, age, parity, education, smoking during pregnancy, breastfeeding duration and sex, higher E-DII in late pregnancy was associated with reduced risks of eczema at age 6 and 12 months (OR 0.89 [95% CI 0.81, 0.99], <i>p</i> = 0.03 and OR 0.91 [0.82, 1.00], <i>p</i> = 0.05, respectively). Consistent with this, higher maternal serum neopterin was associated with a lower risk of eczema at ages 6 months (OR 0.72 [0.51, 1.01], <i>p</i> = 0.05) and 12 months (OR 0.71 [0.53, 0.96], <i>p</i> = 0.03).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The findings suggest that a pro-inflammatory maternal diet and an inflammatory maternal environment during pregnancy may protect the developing infant from Th2 driven inflammation and lower the risk of infantile atopic eczema.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>NCT04715945</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 7","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70080","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144705315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}